Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 15
CXCL13 Is A Biomarker Of Anti-Leucine-Rich Glioma-Inactivated Protein 1 Encephalitis Patients
Authors Lin Y, Yang X, Lv J, Liu X, Wang S
Received 7 July 2019
Accepted for publication 17 September 2019
Published 11 October 2019 Volume 2019:15 Pages 2909—2915
DOI https://doi.org/10.2147/NDT.S222258
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Yuping Ning
You-ting Lin, 1 Xue Yang, 2 Jing-wei Lv, 2 Xue-wu Liu, 2,* Sheng-jun Wang 2,*
1Department of Neurology, Shandong Provincial Hospital, Shandong University, Ji’nan, People’s Republic of China; 2Department of Neurology, Qilu Hospital, Shandong University, Ji’nan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Sheng-jun Wang;Xue-wu Liu
Department of Neurology, Qilu Hospital, Shandong University, 107# Wen Hua Xi Road, Ji’nan 250012, Peoples Republic of China
Email [email protected]; [email protected]
Background: Although antibody-mediated immune responses are considered pathogenic and responsible for neural injury in anti-leucine-rich glioma-inactivated protein 1 (anti-LGI1) encephalitis, previous studies have indicated that cytokines and chemokines might play roles in the pathogenic process by serving as B cell enhancers. In this study, we detected the profiles of cytokines and chemokines in the cerebral fluid (CSF) and serum of patients with anti-LGI1 encephalitis to identify potential biomarkers.
Methods: Sixteen patients diagnosed with anti-LGI1 encephalitis and nine patients diagnosed with noninflammatory neurologic disorders were included in the study. Cytokines and chemokines including IL-6, IL-10, IL-17, CXCL12, CXCL13, BAFF and HMGB1 in serum and CSF were measured.
Results: The serum and CSF levels of CXCL13 were significantly higher in patients with anti-LGI1 encephalitis (36.32± 34.71 pg/mL and 2.23± 2.41 pg/mL, respectively) than in controls (10.84± 5.02 pg/mL and 0.34± 0.21 pg/mL, respectively). There was no significant difference in serum or CSF levels of IL-6, IL-10, IL-17, CXCL12, BAFF and HMGB1 between the two groups.
Conclusion: CXCL13 is a potential biomarker of active inflammation in anti-LGI1 encephalitis. The distinctive response of cytokines and chemokines might be closely linked to the mechanisms underlying this condition.
Keywords: leucine-rich glioma-inactivated protein 1, CXCL13, cytokine, encephalitis, biomarker
A Letter to the Editor has been published for this article.
A Response to Letter has been published for this article.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.